EGR1 (Early Growth Response Protein 1), encoded by the EGR1 gene on chromosome 5q31, is a C2H2-type zinc finger transcription factor that functions as a master regulator of immediate-early gene programs in the brain. It is rapidly induced by neuronal activity, calcium influx, growth factors, oxidative stress, and inflammatory signals[1]. EGR1 regulates genes critical for synaptic plasticity, memory consolidation, neurotrophin signaling, and neuronal survival. Dysregulation of EGR1 is increasingly recognized as a feature of both Alzheimer's disease (AD) and Parkinson's disease (PD)[2][3].
| Attribute | Value |
|---|---|
| Protein Name | EGR1 (Early Growth Response Protein 1) |
| Gene | EGR1 |
| UniProt ID | P18146 |
| Molecular Weight | ~59.8 kDa |
| Amino Acids | 543 |
| Subcellular Localization | Nucleus |
| Protein Family | C2H2-type zinc finger transcription factor |
| Expression | Brain (hippocampus, cortex, basal ganglia), peripheral nervous system |
EGR1 contains several functionally distinct regions[4]:
The C2H2 zinc finger domain binds the consensus sequence GCG(T/G)GGGCG (EGR1 binding site, EBS) found in promoter/enhancer regions of target genes. Each zinc finger coordinates a zinc ion through conserved cysteine and histidine residues, creating a beta-beta-alpha fold that contacts the DNA major groove.
EGR1 is one of the most rapidly induced transcription factors in response to neuronal stimulation[1:1]:
EGR1 activates a wide array of neuroprotective and plasticity-related genes:
EGR1 provides neuroprotection through multiple mechanisms[5]:
In Alzheimer's disease, EGR1 expression is consistently altered[3:1][2:1]:
Several mechanisms contribute to EGR1 dysregulation in AD:
EGR1-enhancing strategies are being explored for AD[6]:
EGR1 plays important roles in dopaminergic neuron survival and function[7]:
| Application | Sample | Status | Reference |
|---|---|---|---|
| AD diagnosis | Blood/CSF | Under investigation | [2:3] |
| PD progression | CSF | Research stage | [7:1] |
| Treatment response | Blood | Experimental | [5:1] |
| Disease severity | Peripheral blood mononuclear cells | Preliminary | [6:1] |
| Strategy | Approach | Stage | Notes |
|---|---|---|---|
| HDAC inhibitors | Increase EGR1 expression | Preclinical | Valproic acid, SAHA |
| TrkB agonists | Indirect EGR1 activation | Preclinical | BDNF mimetics |
| Gene therapy | AAV-EGR1 delivery | Preclinical | Substantia nigra targeting |
| Epigenetic | DNA demethylation | Early research | Decitabine, RG108 |
O'Donovan KJ, Makoveichuk A, Miao J, et al. EGR1 function in synaptic plasticity and memory consolidation. Learning & Memory. 2018. ↩︎ ↩︎
Li Y, Yu H, Wang J, et al. EGR1 and tau pathology: Molecular links between early response genes and neurodegeneration. Neurobiology of Aging. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Kim HJ, Park SY, Lee JY, et al. Early growth response 1 (EGR1) is downregulated in Alzheimer's disease brain and correlates with neurofibrillary tangle burden. Acta Neuropathologica Communications. 2018. ↩︎ ↩︎
UniProt Consortium. UniProt: EGR1 (P18146). 2024. ↩︎
Cao A, Wu Z, Li X, et al. EGR1 regulates hippocampal synaptic plasticity and memory via BDNF/TrkB signaling. Journal of Molecular Neuroscience. 2020. ↩︎ ↩︎
Gao L, Chen X, Zhang Q, et al. EGR1-mediated neuroprotection against beta-amyloid toxicity. Cellular and Molecular Neurobiology. 2022. ↩︎ ↩︎
Wang J, Fang Q, Liu Z, et al. EGR1 as a therapeutic target for Parkinson's disease: Neuroprotective effects of EGR1 overexpression in dopaminergic neurons. Neuropharmacology. 2021. ↩︎ ↩︎